A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis.
A vaccine against herpes genitalis was prepared from the extracellular virus particles from baby hamster kidney cells infected with bovine mammillitis virus (BMV) strain "Allerton". The virus was inactivated by formaldehyde followed by ultracentrifugation to concentrate the virus particles and eliminate formaldehyde to an acceptable concentration for immunisation of human subjects. The vaccine was cross antigenic and cross immunogenic with herpes simplex virus type 1. Thirty-four consorts at high risk of herpes genitalis were immunised with two or three doses each containing 10(9) virus particles equialent to approx. 150 micrograms protein. There has been no evidence of local or general side effect in a follow-up period of over 100 patient years. The immunogenicity and protective efficacy of this vaccine in human subjects will be investigated in a double-blind placebo-controlled trial.
Skinner
G R
GR
University of Birmingham, England.
Buchan
A
A
Davies
J
J
Durham
J
J
Castrucci
G
G
D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D015153:Blotting, Western; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006558:Herpes Genitalis / Q000517:prevention & control*; D001911:Herpesvirus 2, Bovine / Q000276:immunology* / Q000502:physiology; D006801:Humans; D005779:Immunodiffusion; D008297:Male; D051379:Mice; D008875:Middle Aged; D009500:Neutralization Tests; D012747:Sexual Partners; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology; D014771:Virion / Q000276:immunology*; D014779:Virus Replication
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines